These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 34007685

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A review of FDA warning letters and notices of violation issued for patient-reported outcomes promotional claims between 2006 and 2012.
    Symonds T, Hackford C, Abraham L.
    Value Health; 2014 Jun; 17(4):433-7. PubMed ID: 24969004
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021.
    Sams L, Slagle AF, Symonds T, Antonova J, Globe D.
    Value Health; 2023 Dec; 26(12):1675-1680. PubMed ID: 37748736
    [Abstract] [Full Text] [Related]

  • 6. FDA actions against health economic promotions, 2002-2011.
    Neumann PJ, Bliss SK.
    Value Health; 2012 Dec; 15(6):948-53. PubMed ID: 22999146
    [Abstract] [Full Text] [Related]

  • 7. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters.
    Kim H.
    Int J Health Policy Manag; 2015 Aug 25; 4(12):813-21. PubMed ID: 26673465
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
    Bramstedt KA, Kassimatis K.
    Clin Invest Med; 2004 Dec 25; 27(6):316-23. PubMed ID: 15675112
    [Abstract] [Full Text] [Related]

  • 11. Drug Advertising Violations: A Longitudinal Trend Analysis of FDA Enforcement Letters from 2005 to 2019.
    Zagrodney KAP, Sheikhan NY, Pinto A, Sheikhan T, Witek TJ.
    Pharmaceut Med; 2021 Jan 25; 35(1):31-38. PubMed ID: 33453042
    [Abstract] [Full Text] [Related]

  • 12. Health Claims About Cannabidiol Products: A Retrospective Analysis of U.S. Food and Drug Administration Warning Letters from 2015 to 2019.
    Wagoner KG, Lazard AJ, Romero-Sandoval EA, Reboussin BA.
    Cannabis Cannabinoid Res; 2021 Dec 25; 6(6):559-563. PubMed ID: 34142863
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Unsubstantiated health claims for COVID-19 infections are led by cannabidiol: return of snake oil medicine.
    Tran A, Sheikhan NY, Sheikhan T, Nowak DA, Witek TJ.
    J Cannabis Res; 2021 Dec 08; 3(1):49. PubMed ID: 34876238
    [Abstract] [Full Text] [Related]

  • 15. Direct-to-physician and direct-to-consumer advertising: Time to have stringent regulations.
    Kannan S, Gowri S, Tyagi V, Kohli S, Jain R, Kapil P, Bhardwaj A.
    Int J Risk Saf Med; 2015 Dec 08; 27(2):77-83. PubMed ID: 26410010
    [Abstract] [Full Text] [Related]

  • 16. Trend Analysis of FDA Warning Letters Issued to Medical Products About Violations to Current Good Manufacturing Practices (CGMP) Between 2007 and 2014.
    Wang L, Zheng H, Ren X, Sun H.
    Ther Innov Regul Sci; 2016 May 08; 50(3):312-318. PubMed ID: 30227064
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.